search

Active clinical trials for "Lymphoma, T-Cell"

Results 641-650 of 706

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

LymphomaLymphoma11 more

This research study will test OT-82, which is an investigational ("research" or "experimental" ) drug. The study has two stages (Stage 1 and Stage 2). The purpose of Stage 1 is to determine the safety and tolerability and the maximum tolerated dose (MTD) or the maximum tested dose of OT-82 administered orally to participants. The purpose of Stage 2 is to determine the preliminary efficacy of OT-82 in relapsed or refractory lymphoma at the MTD or the maximum tested dose. Both parts of the study will also evaluate the pharmacokinetics (absorption, distribution, metabolism, elimination) of OT-82. OT-82 treatment slowed the growth, reduced the size, or in some cases cured certain cancers in animal studies. It is hoped that participants with relapsed or refractory lymphoma treated with OT - 82 in this study will experience slowing tumor growth and/or reduction of tumor size.

Unknown status47 enrollment criteria

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)

Peripheral T-cell Lymphoma

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

Unknown status2 enrollment criteria

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic Lymphoma1 more

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T cell lymphoma or leukemia

Unknown status9 enrollment criteria

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell...

Peripheral T-cell Lymphoma

This study addresses the hypothesis that intermittent treatment with fenretinide intravenous emulsion will induce objective responses in patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL) who have failed at least one prior systemic therapy and will result in acceptable toxicities.

Unknown status24 enrollment criteria

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Peripheral T-cell Lymphomas

The aim of this study is to evaluate anti-tumor safety and efficacy of endostar®(Human recombinant endostatin injection)combined with traditional GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy for newly diagnosed or relapsed PTCL(aggressive peripheral T-cell lymphomas) patients in phase II clinical study.

Unknown status20 enrollment criteria

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

Extranodal NK/T-cell LymphomaNasal Type

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.

Unknown status16 enrollment criteria

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral...

Peripheral T Cell Lymphoma

The prognosis for Peripheral T cell lymphomas (PTCL) remains poor in comparison to B cell NHL. This is largely due to lower response rates and less durable responses to standard combination chemotherapy regimens such as CHOP. Whether CDOP plus Chidamide can improve the prognosis for PTCL.

Unknown status9 enrollment criteria

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma...

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma15 more

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Unknown status60 enrollment criteria

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Extranodal NK-T-Cell LymphomaNasal and Nasal-Type

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

Unknown status11 enrollment criteria

New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in...

Lymphoma

The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of L-asparaginase plus DICE regimen in the patients with early stage NK/T-cell lymphoma.

Unknown status9 enrollment criteria
1...646566...71

Need Help? Contact our team!


We'll reach out to this number within 24 hrs